Ingenol Mebutate: A Succinct Review of a Succinct Therapy

被引：26

作者：

Alchin D.R. ^{[1
]}

机构：

[1] The University of Melbourne, Parkville

来源：

Dermatology and Therapy | 2014年 / 4卷 / 2期

关键词：

Actinic keratosis; Dermatology; Field therapy; Ingenol; 3-angelate; Ingenol mebutate; Picato; Solar keratosis; Squamous cell carcinoma;

D O I：

10.1007/s13555-014-0061-2

中图分类号：

学科分类号：

摘要：

Background: Ingenol mebutate is a newly approved topical field therapy for actinic keratosis (AK). It has a dual mechanism of action comprising of a rapid induction of necrosis that specifically targets dysplastic cells, as well as neutrophil-mediated immunostimulatory effects. Such a dual mechanism allows for this agent to clear AK lesions in as little as two to three daily applications, thus providing for improved treatment outcomes and patient satisfaction.; Review: Given that this is a new dermatologic therapy, this review summarizes the key literature surrounding this agent. This review covers the indications for use, mechanisms of action, method of administration, efficacy and safety profile and important drug interactions of ingenol mebutate.; Conclusions: Ingenol mebutate should be considered a highly relevant field therapy for AK and the prevention of progression to squamous cell carcinoma. © 2014, The Author(s).

引用

页码：157 / 164

页数：8

共 20 条

[1]

Berman B., Cockerell C.J., Pathobiology of actinic keratosis: ultraviolet-dependent keratinocyte proliferation, J Am Acad Dermatol, 68, 1, pp. S10-S19, (2013)

[2]

Sotiriou E., Apalla Z., Vrani F., Lallas A., Chovarda E., Ioannides D., Photodynamic therapy vs. imiquimod 5% cream as skin cancer preventive strategies in patients with field changes: a randomized intra individual comparison study, JEADV, (2014)

[3]

Chia A., Lim A., Shumack S., Moreno G., Actinic keratoses, Aust Fam Phys, 36, 7, (2007)

[4]

Goldenberg G., Optimal treatment of actinic keratosis, Clin Interv Aging, 9, pp. 15-16, (2014)

[5]

Perl M., Goldenberg G., Field therapy in the treatment of actinic keratosis, Cutis, 93, 4, pp. 172-173, (2014)

[6]

Dodds A., Chia A., Shumack S., Actinic keratosis: rationale and management, Dermatol Ther (Heidelb), 4, 1, pp. 11-31, (2014)

[7]

Lebwohl M., Shumack S., Stein Gold L., Melgaard A., Larsson T., Tyring S.K., Long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses, JAMA Dermatol, 149, 6, pp. 666-670, (2013)

[8]

Siller G., Rosen R., Freeman M., Welburn P., Katsamas J., Ogbourne S.M., PEP005 (ingenol mebutate) gel for the topical treatment of superficial basal cell carcinoma: results of a randomized phase IIa trial, Australas J Dermatol, 51, 2, pp. 99-105, (2010)

[9]

Gupta A.K., Paquet M., Ingenol mebutate: a promising treatment for actinic keratoses and nonmelanoma skin cancers, J Cutan Med Surg, 17, 3, pp. 173-179, (2013)

[10]

Anderson L., Schmieder G.J., Werschler W.P., Tschen E.H., Ling M.R., Stough D.B., Et al., Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis, J Am Acad Dermatol, 60, 6, pp. 934-943, (2009)

← 1 2 →